EUVIMEDEUVIMED entdecken
Crossref

Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse model

Anders Örbom, Susan Evans-Axelsson, Bo Jansson, Oskar Vilhelmsson Timmermand, Thuy A Tran, Anders Bjartell, Sven-Erik Strand

Nuklearmedizin - NuclearMedicine · 01.04.2025 · 64 (02) · 163-169

DOI: 10.1055/a-2543-0723 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.04.2025. Verfasst von Anders Örbom und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Oncology, Lund University Department of Clinical Sciences Lund, Lund, Sweden. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Intercellular Adhesion Molecule-1, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Government funding of clinical research within the national health service, Lund University, Sweden, Cancerfonden, Eurostars.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite new therapies, castration-resistant prostate cancer (CRPC) is still incurable. Intercellular Adhesion Molecule 1 (ICAM-1) is a well-characterized cell surface protein involved in prostate cancer pathogenesis, differentially expressed during transition from hormone-sensitive to CRPC. This study aimed to investigate ICAM-1 as a target for imaging and radioimmunotherapy of CRPC. Anti-ICAM-1 antibody R6.5 was labeled with 111In or 177Lu, and a non-specific antibody with 177Lu. In vitro uptake of R6.5 was tested in PC-3 prostate cancer cells. Biodistribution studies, SPECT/CT imaging, and autoradiography were performed in a PC-3 xenograft model. In vitro uptake of R6.5 ([177Lu]Lu-R6.5) increased during 6 h of incubation. The uptake was higher at lower mAb concentration and could be blocked by 500 nM of unlabeled R6.5. In vivo and ex vivo biodistribution showed that [111In]In-R6.5 and [177Lu]Lu-R6.5 targeted the xenograft tumors better than the control Ab, however [111In]In-R6.5 had better tumor uptake than [177Lu]Lu-R6.5, probably due to less aggressive conjugation with chelator and smaller tumor sizes. From 24 h post-injection, the tumors in mice injected with [111In]In-R6.5 and [177Lu]Lu-R6.5 were visible on SPECT, optimal contrast at 48 h. Uptake was low in normal organs except the spleen and liver for all mAbs. Autoradiography showed [111In]In-R6.5 and [177Lu]Lu-R6.5 accumulated along the edges of viable tumor. The control Ab tended to accumulate in partly necrotic areas. This study demonstrates ICAM-1 as a potential target for theragnostics in CRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalIntercellular Adhesion Molecule-1Prostatic NeoplasmsAnimalsMaleMiceTissue DistributionHumansSingle Photon Emission Computed Tomography Computed TomographyCell Line, TumorDisease Models, AnimalIndium RadioisotopesRadiopharmaceuticals

Substanzen

Antibodies, MonoclonalIntercellular Adhesion Molecule-1Indium RadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Section of Oncology, Lund University Department of Clinical Sciences Lund, Lund, Sweden.
  • Section of Urological cancers, Department of Translational Medicine, Lund University Faculty of Medicine, Lund, Sweden.
  • Section of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lund University Faculty of Medicine, Lund, Sweden.
  • Department of Radiopharmacy, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden.
  • Medical Radiation Physics, Lund University Department of Clinical Sciences Lund, Lund, Sweden.

Förderung

  • Government funding of clinical research within the national health service, Lund University, Sweden
  • Cancerfonden
  • Eurostars
  • Gunnar Nilssons Cancerstiftelse
  • Vetenskapsrådet

Zitieren

APA

Örbom, A., Evans-Axelsson, S., Jansson, B., Vilhelmsson Timmermand, O., Tran, T. A., Bjartell, A., & Strand, S. E. (2025). Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse model. Nuklearmedizin - NuclearMedicine, 64(02), 163-169. https://doi.org/10.1055/a-2543-0723

Vancouver

Örbom A, Evans-Axelsson S, Jansson B, Vilhelmsson Timmermand O, Tran TA, Bjartell A, et al. Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse model. Nuklearmedizin - NuclearMedicine. 2025;64(02):163-169. doi:10.1055/a-2543-0723

BibTeX
@article{rbom2025,
  author = {Örbom, Anders and Evans-Axelsson, Susan and Jansson, Bo and Vilhelmsson Timmermand, Oskar and Tran, Thuy A and Bjartell, Anders and Strand, Sven-Erik},
  title = {Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse model},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2025},
  volume = {64},
  number = {02},
  pages = {163--169},
  doi = {10.1055/a-2543-0723}
}
Kostenlos starten →